Table 3 Selected characteristics of the 25 studies.
Study design | Case-control | 16/25 (64.0%) |
Cohort | 9/25 (36.0%) | |
Region | US | 9/25 (36.0%) |
Europe | 10/25 (40.0%) | |
Asia | 6/25 (24.0%) | |
HPV detection method | ISH (without PCR) | 5/25 (20.0%) |
PCR-based | 20/25 (80.0%) | |
L1-target | 15/20 (75%) | |
E6/E7-target | 5/20 (25%) | |
Rate of HPV+ HNSCC | Tumor size (T) | 5/9 (55.6%) |
Cervical lymph node metastases (N) | 6/9 (66.7%) | |
Advanced UICC tumor stage | 6/11 (54.5%) | |
OPSCC localisation | 7/7 (100%) | |
Low grading of cancer | 5/7 (71.4%) | |
Non-drinking | 4/11 (36.4%) | |
Non-smoking | 8/14 (57.1%) | |
p16 + | 13/16 (81.3%) | |
Younger age | 7/12 (58.3%) | |
Gender | 1/9 (11.1%) |
